Cytek Biosciences, Inc.CTKBNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank33
3Y CAGR-16.4%
Studio
Year-over-Year Change

Price-to-book ratio

3Y CAGR
-16.4%/yr
Annual compound
Percentile
P33
Within normal range
vs 3Y Ago
0.6x
Contraction
Streak
4 yr
Consecutive declineElevated
PeriodValueYoY Change
20251.89-11.9%
20242.14-31.8%
20233.14-2.8%
20223.23-40.1%
20215.39+103.5%
2020-155.66-160.2%
2019-59.83-